TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07509892: A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial Evaluating the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 198 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,279,500

Rescue Site Savings

+$4,795,500

Unlock Full NCT07509892 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07509892 Rescue Dossier →